Is Moderna Stock A Buy After Reiterating Its Guide After Pfizer ' s Cut?

stock collapsed in mid-October after rival Pfizer (PFE) slashed about $9 billion from its full-year outlook due to declining demand for Covid products. But Moderna retained its guide for $6 billion to $8 billion in full-year sales of Covid vaccine, Spikevax. The company noted the outlook,…#pfe #spikevax #nvax #sanofi #gsk #merck #immatics #carsgen #moderna #fda
Source: Reuters: Health - Category: Consumer Health News Source Type: news